- Home
- XERS vs EMO Comparison
XERS vs EMO Comparison
Compare XERS & EMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | EMO |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.3M | 1.0B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | XERS | EMO |
|---|---|---|
| Price | $5.48 | $53.43 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $10.83 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 51.4K |
| Earning Date | 03-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.70% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $28.65 | N/A |
| Revenue Next Year | $18.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $3.81 | $41.54 |
| 52 Week High | $10.08 | $53.99 |
Technical Indicators
Market Signals| Indicator | XERS | EMO |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 70.89 |
| Support Level | $4.30 | $46.50 |
| Resistance Level | $5.49 | $53.99 |
| Average True Range (ATR) | 0.24 | 0.84 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 12.43 | 75.44 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.